<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE collection SYSTEM "BioC.dtd">
<collection><source>PMC</source><date>20220803</date><key>pmc.key</key><document><id>9330984</id><infon key="license">CC BY</infon><passage><infon key="article-id_doi">10.1186/s42269-022-00886-x</infon><infon key="article-id_pmc">9330984</infon><infon key="article-id_pmid">35915785</infon><infon key="article-id_publisher-id">886</infon><infon key="elocation-id">222</infon><infon key="issue">1</infon><infon key="kwd">COVID-19 HDL-Apo-lipoprotein A1 Elderly subjects Chronic illness Hemoglobin-haptoglobin-hemopexin Apo-A1 mimetic peptide D-4F ω-3 polyunsaturated fatty acids Saussurea lappa (costus) ApoM-sphingosine-1-phosphate</infon><infon key="license">Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.</infon><infon key="name_0">surname:AbdelHafez;given-names:Mohamed Aly</infon><infon key="section_type">TITLE</infon><infon key="title">Keywords</infon><infon key="type">front</infon><infon key="volume">46</infon><infon key="year">2022</infon><offset>0</offset><text>Protective and therapeutic potentials of HDL and ApoA1 in COVID-19 elderly and chronic illness patients</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>104</offset><text>Background</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>115</offset><text>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for coronavirus disease-2019 (COVID-19). Elderly subjects, obese, and patients with chronic illnesses, are the most affected group. HDL has pleiotropic physiological functions that are affected with alteration(s) in its structure.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>422</offset><text>Main text</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>432</offset><text>Inflammation whether septic, immune, or other affects HDL structure and function. COVID-19 is associated with systemic immune-inflammation due to cytokine surge. Viral interaction with erythrocytes and hemoglobin-related compounds (may cause anemia and hypoxia) and other factors may affect HDL function. Trials have been conducted to resume HDL functions using peptide preparation, nutritional, and herbal elements.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>849</offset><text>Conclusions</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>861</offset><text>In this review article, I’ll discuss the use of reconstituted HDL (rHDL), Apo-A1 mimetic peptide D-4F, ω-3 polyunsaturated fatty acids, and the powdered roots and/or extract of Saussurea lappa (costus) to avoid comorbidity and mortality of COVID-19 in patients with chronic illness or elderly-age mortality.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1173</offset><text>Background</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1184</offset><text>HDL has multiple physiological functions; i.e. reverse cholesterol transport, anti-inflammatory, anti-thrombotic, anti-oxidative, anti-apoptotic in addition to protection of vascular endothelium against damage and leakage of small particles like LDL to pass through. Apo-lipoprotein A1 (Apo-A1) is the main apo-lipoprotein component and plays an axial role in HDL function. Alterations of HDL disturb its functions. Elderly subjects, obese patiens, and patients with chronic illness such as diabetes, cardiovascular disease (CVD) or chronic inflammatory diseases have bad comorbidity among COVID19 patients. Inflammation affect HDL structure and function. COVID-19 causes systemic immune-inflammation due to cytokine explosion, viral interaction with erythrocytes and its hemoglobin content and other factors influencing HDL function. Clinical and experimental trials suggest that resuming the HDL function by administration of reconstituted HDL, Apo-A1 mimetic peptide D-4F, ω-3 polyunsaturated fatty acids, and/or the powdered roots of Saussurea costus ameliorates the clinical outcome. We recommend application of these to regain HDL protective function in the fore-mentioned cases.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>2374</offset><text>Main text</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>2384</offset><text>HDL structure and function</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_3</infon><offset>2411</offset><text>Reverse cholesterol transport (RCT)</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2447</offset><text>Apolipoprotein Apo A-1 interacts with ATP-binding cassette-1 (ABCA1) in various cell types (hepatocytes, enterocytes, and macrophages). Cholesterol and phospholipids are combined in this interaction to form nascent HDL particles (pre-HDL, or HDL3), which are discoid HDL. Other apolipoproteins may be added, except for Apo-B.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2773</offset><text>Cholesterol is esterified with unsaturated fatty acid of lethicin to form a mature molecule of HDL (α-HDL or HDL2); catalyzed by lecithin-cholesterol acyltransferase (LCAT). Cholesterol ester is transferred to Apo B-100-containing lipoproteins, especially to the low-density lipoprotein (LDL), in exchange for triacylglycerol to form spheroid HDL. Apo B-100-containing lipoprotein binds to LDL-receptor on the hepatocyte surface and undergoes endocytosis to eliminate its cholesterol content. Mature HDL interacts with scavenger receptor-B1 (SR-B1) in the liver, this allows the transfer of its cholesterol content as well as triacylglycerol (TG). By release of TG, the remained HDL molecule, the pre-β HDL (HDL3) circulates and repeat the RCT process (Steck and Lange).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3551</offset><text>In addition to Apo A-1, HDL particles contain ApoM, enzymes involved in antioxidative mechanisms such as paraoxonase-1, lecithin-cholesterol acyltransferase, and diverse lipid species, including cholesterol esters, triglycerides, phospholipids, and bioactive sphingolipids such as sphingosine 1-phosphate (S1P) (Nofer et al.). In the systemic circulation, about 60% of plasma S1P is bound to apolipoprotein M (apoM) (Kurano and Yatomi). S1P signals through specific G proteins. It inhibits vascular permeability and is required for vascular development as well as immune cell trafficking (Liu et al.). ApoM is involved in an anti-inflammatory signalling complex that inhibits NF-B-dependent inflammatory pathways. The NF-κB pathway is a key inflammatory signaling pathway induced by TNFα (Galvani et al.).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>4365</offset><text>Disturbed HDL protective function against oxidation and inflammation</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4434</offset><text>HDL anti-oxidant function is attributed to paraoxonase-1 (PON-1) enzyme (James et al.). Variation in paraoxonase-1 activity is recorded in atherosclerosis and other inflammatory states (Soran et al.).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4635</offset><text>Exposure of HDL to oxidation stress, e.g. at sites of inflammation, diminishes Apo A1 activity (Zheng et al.), and the LCAT biological function (Shao et al.) resulting in disturbed HDL turnover.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4830</offset><text>Systemic inflammation can also contribute to the observed hypoxia-mediated HDL impaired activity (Biolo et al.). Owing to their small particle size, LDL get access into extracellular fluid to be in direct contact with tissue cells. Reactive oxygen species (ROS) are generated in tissues owing to cycloxogenase, lipooxygenase, myeloperoxidase, and/or NADPH oxidase exaggerated activity during inflammatory process. LDL is oxidized into oxy-LDL. HDL3 (pre-β-HDL), protect LDL from oxidative damage by free radicals (Kontush and Chapman). Native Apo A-I inhibits the proinflammatory effect of oxidized lipids (Navab et al.). At sites of inflammation, myeloperoxidase bound to HDL, catalyzes its oxidation to a proinflammatory particle (Undurti et al.) as evidenced by elevation of CRP (Corsetti et al.). Fatty acids moieties of phospholipids in plasma membranes and lipoproteins are oxidized to lipid hydroperoxides. Lipid hydroperoxides migrate from the surface of LDL to be transfered to the liver via SR-B1 and/or to be carried by HDLs (Bowry et al.). The imbalance in the antioxidant system causes oxHDL modification. Oxidized lipids enhance circulating macrophages to release pro‐inflammatory cytokines (Van Lenten et al.). Cytokines decrease synthesis and/or secretion of lipoproteins including Apo-AI which are steadily decreased as the disease progress to critically ill state.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>6216</offset><text>Inflamattory cytokines increase the activity of secretory phospholipase A2 (sPLA2) and endothelial cell lipase, enzymes that metabolize key HDL constituents (Filippas-Ntekouanet et al.). Insulin resistance reduces lipoprotein lipase (LPL) activity (Popko et al.). Clearance of triglyceride content of chylomicrons and VLDL is blunted. Transfer of cholesteryl-esters from HDL to ApoB-lipoprotein series is inhibited. Hence, cholesterol efflux from peripheral tissues is retarded. Altered HDL-apolipoprotein structure inhibits release and activation of hepatic lipase with elevation of plasma TG (Chatterjee and Sparks). Hypertriglyceridemia is among the factors potentiating cardiometabolic risk (Moriyama and Takahashi). Plasma levels of apoM in diabetics is reduced as compared with euglycemic control subjects. ApoA-I, apoM, and S1P in insulin resistance are decreased (Kurano et al.).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>7104</offset><text>Serum amyloid A (SAA) may displace ApoA-I in HDL particles, leading to increased catabolism of HDL (McEneny et al.). This is an additional factor responsible for shifting the function of HDL from a vasoprotective to a pro-atherosclerotic lipoprotein (Zewinger et al.). SAA plasma levels are progressively elevated with COVID‐19 disease severity, so a prognosis of the disease could be evaluated (Li et al.).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>7514</offset><text>Low HDL-C levels consist a poor prognostic factor for COVID-19 severity (Agouridis et al.). High HDL-C levels were associated with a lower risk of hospitalization due to COVID19 infection (Lassale et al.). Serum ApoA1 is reduced with the progress of illness in COVID-19 patients (Yang et al.).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>7808</offset><text>Interaction of hemoglobin and related molecules with HDL</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>7865</offset><text>Normally, HDL is bound at low levels of hemoglobin associated to its Apo A-I fraction. Hemoglobin / HDL is increased in inflammatory states. Haptoglobin is a protein synthesized by the liver to bind circulating plasma free hemoglobin and facilitate its association to HDL (Watanabe et al.). Hemopexin, a protein involved in iron transport, is identified among HDL proteins. The interaction of hemoglobin, haptoglobin, and hemopexin with HDL is positively correlated with the proinflammatory properties of HDL during systemic inflammation so that it reduces the activity of Apo A1 (Spagnuolo et al. 2005). Accordingly, increased HDL linked hemoglobin may contribute for higher levels of lipid hydroperoxides besides acquiring proinflammatory characteristics (Watanabe et al.).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>8641</offset><text>Interaction of SARS-CoV-2 infection with erythrocytes</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>8695</offset><text>The viral effect on heme metabolism is due to binding of viral surface glycoprotein with the beta-chains of hemoglobin (Wenzhong and Hualan.) resulting in hemoglobin denaturation (Wenzhong and Hualan.). Hence, SARS-CoV-2 may induce hemolysis. During the course of the disease, anemia progresses and hemoglobin-related pathology also progresses. Hemoglobin/iron interrelation may result in multi-organ disorders and systemic hypoxia.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>9128</offset><text>An additional receptor, CD147, was identified besides angiotensin converting enzyme 2 (ACE2) on erythrocytes and other cells (Wang et al.). CD147 may be the routes through which the virus get access into the erythrocytes, bone marrow immature cells (Ulrich and Pillat). Cardiac pericytes, vascular smooth muscles and probably vascular endothelium may be invaded by the virus through CD147 (Robinson et al.).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>9536</offset><text>Hypoxia, which develops as a sequence of erythrocytic hemoglobin and cardiovascular affection, may upregulate CD147 expression. Obese and diabetics overexpress CD147 receptors in erythrocytes (Radzikowska et al.). This finding may add an explanation of comorbidity of COVID-19 in obese and diabetic subjects.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>9845</offset><text>Dysorganisation of iron metabolism in SARS-CoV-2 infection</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>9904</offset><text>Infection with SARS-CoV-2 has hepcidin-like activity, probably mediated by IL-6 induced gene expression. Hepcidin facilitates iron accumulation in cells via downregulation of ferroportin (Means Jr). The latter is the key transporter of iron outside the cells. Plasma iron is decreased (hypoferremia) with higher ferritin concentration (hyperferritinemia) (Nemeth et al.). Erythropoiesis becomes inadequate resulting in anemia of inflammation (Ganz and Nemeth). Since blood S1P, bound to HDL-apoM, is linked to number of erythrocytes (Hänel et al.), anemia is associated with decrease in plasma S1P and the circulating S1P is prognostic and predictive biomarker in COVID-19 patients (Marfia et al.). Serum iron ensues contributing to hypoferremia (Drakesmith and Prentice). Increased intracellular iron content potentiates SARS-CoV-2 replication in affected cells (Kalyanaraman). Early in COVID-19 patients, cell iron overload is tolerated without apparent hypoxia. According to Fenton reaction, iron is a potent pro-oxidant; that increases reactive oxygen species (ROS) creating oxidation stress state. ROS activates nuclear factor-kappa B kinase (Lingappan); potentiating the inflammatory response. Furthermore, increased intracellular iron upregulates the expression of inflammatory factors such as IL-6, IL-8, and TNF-α, which in turn, aggravate cytokine surge (Girelli et al.). Concurrently, anemia caused by lower hemoglobin level and hyperferritinemia, besides hemoglobinopathy (caused by SARS-Cov-2 binding to β-chain of hemoglobin) are risk factors contributing to bad comorbidity of mild case to critically-ill condition (Zhou et al.).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>11556</offset><text>Effect of hypoxia</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>11574</offset><text>Hypoxia changes lipoprotein pattern in an atherogenic direction by lowering HDL-C particularly, HDL2-C (Biolo et al.).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>11693</offset><text>Hypoxia induces release of hypoxia inducible factor-1 (HIF-1). Hypoxia and HIF-1α can either stimulate or inhibit cytokine-mediated inflammatory response. The stimulation process depends on upregulation of vascular endothelial growth factor (VEGF) from vascular endothelium. VEGF is among factors that contributes for pathogenicity of severe COVID-19 (Teuwen et al.), by recruiting circulating neutrophils, macrophages, mast cells, and dendritic cells. These cells as well as vascular endothelial cells release ROS and proteases besides cytokines, adhesive molecules, and chemoattractants (monocyte chemo-attractant protein-1, interleukin-1 β, and chemical cytokine-2). VEGF increases cytokine expression and vascular permeability (Shibuya). These factors are responsible for progress of the pathological critical–ill status.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>12526</offset><text>Hypoxia, in addition, triggers mitochondrial dysorganization, altering the mitochondrial membrane permeability so that ROS generation increases and ATP generation is depressed. Post-inflammatory cell damage releases its content of ATP into the extracellular matrix that increases tissue content of adenosine. Adenosine is an anti-inflammatory factor (Rajasundaram). On the other hand, hypoxia induced HIF-1α switches metabolism to anerobic glycolysis which promotes the accumulation of adenosine in an attempt to combat inflammation (Sitkovsky et al.). This might be a protective measure in the course of the disease.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>13148</offset><text>Resolving mediators in COVID-19</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>13180</offset><text>Persistence and continuity of the inflammatory response is driven by the “cytokine storm,” which is triggered by release of the pro‐inflammatory cytokines throughout the course of the disease. Other influencing factors are oxidation stress, altered lipoprotein structure and function, hypoxia, and changes in hemoglobin-interacting compounds.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>13529</offset><text>Recovery from the disease condition is not a passive mechanism that depends just on elimination of these factors. Rather, it is an active process initiated by what are so-called specialized pro-resolving mediators (SPMs).These are lipid mediators derived from ω3-polyunsturated fatty acids linked to phospholipids of plasma membrane of macrophages and neutrophils as well as lipoprotein phospholipids (Serhan et al.). There are two series of SPMs, E-series derived from eicosapentaenoic acid (EPA); resolvins, and D‐series derived from docosahexaenoic acid (DHA); protectins and maresins. ω3-Fatty acids (EPA and DHA) compete with ω6-polyunsaturated fatty acid; arachidonic acid (the precursor of proinflammatory mediators) for cyclooxygenase and lipooxygenase enzymes, thus inhibiting biosynthesis of prostaglandins, leukotrienes, thromboxaneA2, and lipoxins. SPMs potentiate phagocytosis of apoptotic cells and cell debris left in the inflammatory process by phagocytic cells (the so-called “efferocytosis”) (Serhan et al.). This process pivots on recovery from the inflammatory state (El Kebir et al.). It has been reported that DHA‐derived protectin D1, is a suppressor of influenza virus replication and regresses its severe symptoms (Morita et al.). Combination of acetyl salicylic acid with EPA and/or DHA ameliorate severe respiratory symptoms and coagulopathy features in patients with COVID-19 (Das). Obese subjects have SPM deficits. This may be responsible for the worse morbidity of their COVID‐19 course owing to lack of these resolution factors (Pal et al.). EPA- and DHA-linked HDL improves it antioxidant and enzyme functions (Cartolano et al).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>15204</offset><text>Saussurea lappa (costus); phytotherapeutic agent</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>15253</offset><text>Saussurea lappa (costus) is a plant well-known about 2,500 years ago and used traditionally in the Indian and Arab systems of medicine. Mostly the essential root oil and root powder were used for the medicinal purposes (Nikhat and Fazil). Saussurea lappa (SL) has anti-inflammatory activity as documented by reduction of RNA expression of inflammatory cytokines: TNF-α, GM-CSF and IL1β and metalloprotease-9 activity (Lammari et al.). It inhibits protein and mRNA expression of interleukin-1b (IL-1b) as well as inhibition of phosphorylation of mitogen activated protein kinases (MAPK) (Kang et al.). It suppresses expression of hepatitis B surface antigen (HBsAg) in human hepatoma Hep3B cells in a dose-dependent manner (Chen et al.) and ameliorates chronic hepatitis B (Ansari et al.) suggesting anti-viral activity. Besides, SL components have anti-diabetic, and anti-lipidemic activities (Gomaa et al) raising the possibility of improving HDL levels and functions. It has been reported to be effective in prevention and treatment of COVID-19 by a research group in Upper Egypt. Their findings were published in a local Periodical by Saif-Al-Islam M, and colleagues (Sohag Med J. 2020; 24(3): 6–1).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>16463</offset><text>Targeting therapeutic and preventive potentials of HDL</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>16518</offset><text>It is essentially important for healthy elderly who potentially have low levels of healthy functioning HDL-ApA1 to protect them from caching this life-threatening disease; covid-19. Elderly subjects with chronic Illnesses (diabetes mellitus, obesity, chronic CVD, obstructive airway diseases, hematological diseases, autoimmune diseases), or immune-compromised subjects are also candidates of applying preventive measures.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>16941</offset><text>Considering the functions of HDL and its composition that is altered during acute-phase response; the oxidative status at a site of inflammation modifies HDL proteins, making them proinflammatory besides loss of its anti-oxidant property. The increased association of HDL-hemoglobin-haptoglobin-hemopexin potentiates these changes in addition to inflammatory anemia and increasing hypoxia. HDLs from patients with COVID-19 are less protective in endothelial cells stimulated by TNFα. In these conditions, HDL inhibition of apoptosis was blunted in COVID-19 (Begue et al.).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>17518</offset><text>Reconstituted HDL (rHDL) containing pre-β HDL (HDL3) supplementation, could be a preventive and/or therapeutic target against COVID-19. Difficulties in preparation and supply are a limitation to achieve this purpose. Some investigators have been used Apo A-I mimetic peptide D-4F. D-4F is N-terminal acetylated and C-terminal amidated apoA-I mimetic peptide, Ac-D-W-F-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-NH2 that is synthesized from 18 D-amino acids (Navab et al.). D-4F potentiates the anti-inflammatory function of HDL and recover the reverse cholesterol transport (Bloedon et al.). It recovers anti-oxidant function of HDL by increasing the PON-1 activity in mice leading to decreased plasma levels of oxidized fatty acids (Navab et al.). Many physiological functions of HDL were regained in experimental animals by using D-4F peptide (Dai et al.; Smythies et al.).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>18384</offset><text>Inclusion of ω3-fatty acids EPA and DHA (as precursors of resolvins, protectins and maresins), in the therapeutic protocol of COVID-19 may be valuable in suppressing the inflammatory process. Their use early in the disease is recommended to suppress the inflammatory reactions and to eliminate the tissue debris left by necrobiosis (Sorokin et al.). They, in addition, enhance viral clearance through interrupting the viral enveloped protein formation (Pal et al.). Arachidonic acid being the precursor of pro-inflammatory prostanoids; its use is not recommended in this respect.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>18968</offset><text>Conclusions</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>18980</offset><text>Apo-A1 mimetic peptide D-4F, ω-3 polyunsaturated fatty acids, and the powdered roots and/or extract of Saussurea lappa (costus) are suggested means for resuming HDL-ApA1 physiological activity aiming at protecting elderly and chronically ill patients and reducing the morbidity of COVID-19. More investigations may be recommended for safety and efficacy.</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">title</infon><offset>19339</offset><text>Abbreviations</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19353</offset><text>α-HDL-C</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19365</offset><text>Alpha high density lipoprotein-cholesterol</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19408</offset><text>ABCA1</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19414</offset><text>ATP-binding cassette-1</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19437</offset><text>ABCG1</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19443</offset><text>ATP-binding cassette-G1</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19467</offset><text>Apo-A1</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19474</offset><text>Apo-lipoprotein A1</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19493</offset><text>Apo-M</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19499</offset><text>Apolipoprotein M</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19516</offset><text>CETP</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19521</offset><text>Cholesteryl ester transfer protein</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19556</offset><text>COVID-19</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19565</offset><text>Coronavirus disease-2019</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19590</offset><text>CRP</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19594</offset><text>C-reactive protein</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19613</offset><text>CVD</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19617</offset><text>Cardiovascular disease</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19640</offset><text>D-4F</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19645</offset><text>Apo A-I mimetic peptide made of 18 D-amino acids of which 4 residues of phenylalanine.</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19732</offset><text>DHA</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19736</offset><text>Docosahexaenoic acid</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19757</offset><text>EPA</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19761</offset><text>Eicosapentaenoic acid</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19783</offset><text>HDL-ApA1</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19792</offset><text>High-density apolipoprotein A1</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19823</offset><text>HIF-1</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19829</offset><text>Hypoxia inducible factor-1</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19856</offset><text>IL‐6</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19863</offset><text>Interleukin-6</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19877</offset><text>LCAT</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19882</offset><text>Lecithin-cholesterol acyltransferase</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19919</offset><text>PON-1</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19925</offset><text>Paraoxonase-1</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19939</offset><text>RCT</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19943</offset><text>Reverse cholesterol transport</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19973</offset><text>rHDL</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19978</offset><text>Reconstituted HDL</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>19996</offset><text>ROS</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>20000</offset><text>Reactive oxygen species</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>20024</offset><text>S-1-P</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>20030</offset><text>Sphingosine-1-phosphate</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>20054</offset><text>SAA</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>20058</offset><text>Serum amyloid A</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>20074</offset><text>SARS-CoV-2</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>20085</offset><text>Severe acute respiratory syndrome coronavirus-2</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>20133</offset><text>sPLA2</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>20139</offset><text>Secretory phospholipase A2</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>20166</offset><text>SL</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>20169</offset><text> Saussurea lappa </text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>20187</offset><text>SPMs</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>20192</offset><text>Specialized pro-resolving mediators</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>20228</offset><text>SR-B1</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>20234</offset><text>Scavenger receptors B1</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>20257</offset><text>TG</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>20260</offset><text>Triacylglycerol</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>20276</offset><text>TLR</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>20280</offset><text>Toll-like receptor</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>20299</offset><text>TNF‐α</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>20309</offset><text>Tumor necrosis factor‐alpha</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>20339</offset><text>VEGF</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>20344</offset><text>Vascular endothelial growth factor</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">footnote</infon><offset>20379</offset><text>Publisher's Note</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">footnote</infon><offset>20396</offset><text>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">title</infon><offset>20515</offset><text>Author contributions</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>20536</offset><text>The author read and approved the final manuscript.</text></passage><passage><infon key="section_type">ACK_FUND</infon><infon key="type">title</infon><offset>20587</offset><text>Funding</text></passage><passage><infon key="section_type">ACK_FUND</infon><infon key="type">paragraph</infon><offset>20595</offset><text>Not applicable.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title</infon><offset>20611</offset><text>Availability of data and materials</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>20646</offset><text>Not applicable.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title</infon><offset>20662</offset><text>Declarations</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title</infon><offset>20675</offset><text>Ethics approval and consent to participate</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>20718</offset><text>Not applicable.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title</infon><offset>20734</offset><text>Consent for publication</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>20758</offset><text>Not applicable.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title</infon><offset>20774</offset><text>Competing interests</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>20794</offset><text>The author declares that he has no competing interests.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>20850</offset><text>References</text></passage><passage><infon key="fpage">1</infon><infon key="lpage">9</infon><infon key="name_0">surname:Agouridis;given-names:AP</infon><infon key="name_1">surname:Pagkali;given-names:A</infon><infon key="name_2">surname:Zintzaras;given-names:E</infon><infon key="pub-id_doi">10.1016/j.athplu.2021.08.007</infon><infon key="pub-id_pmid">34622242</infon><infon key="section_type">REF</infon><infon key="source">Atherosclerosis plus</infon><infon key="type">ref</infon><infon key="volume">44</infon><infon key="year">2021</infon><offset>20861</offset><text>High-density lipoprotein cholesterol: a marker of COVID-19 infection severity?</text></passage><passage><infon key="fpage">282</infon><infon key="lpage">290</infon><infon key="name_0">surname:Ansari;given-names:S</infon><infon key="name_1">surname:Siddiqui;given-names:MA</infon><infon key="name_2">surname:Malhotra;given-names:S</infon><infon key="name_3">surname:Maaz;given-names:M</infon><infon key="pub-id_doi">10.4103/pr.pr_157_17</infon><infon key="section_type">REF</infon><infon key="source">Phcog Res</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2018</infon><offset>20940</offset><text>Antiviral efficacy of qust (Saussurea lappa) and afsanteen (Artemisia absinthium) for chronic Hepatitis B: a prospective single-arm pilot clinical trial</text></passage><passage><infon key="fpage">2291</infon><infon key="name_0">surname:Begue;given-names:F</infon><infon key="name_1">surname:Tanaka;given-names:S</infon><infon key="name_2">surname:Mouktadi;given-names:Z</infon><infon key="name_3">surname:Rondeau;given-names:P</infon><infon key="name_4">surname:Veeren;given-names:B</infon><infon key="pub-id_doi">10.1038/s41598-021-81638-1</infon><infon key="pub-id_pmid">33504824</infon><infon key="section_type">REF</infon><infon key="source">Sci Rep</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">2021</infon><offset>21093</offset><text>Altered high-density lipoprotein composition and functions during severe COVID-19</text></passage><passage><infon key="fpage">1000</infon><infon key="name_0">surname:Biolo;given-names:G</infon><infon key="name_1">surname:Di Girolamo;given-names:FG</infon><infon key="name_2">surname:McDonnel;given-names:A</infon><infon key="pub-id_doi">10.3389/fphys.2018.01000</infon><infon key="pub-id_pmid">30104982</infon><infon key="section_type">REF</infon><infon key="source">Front Physiol</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2018</infon><offset>21175</offset><text>Effects of hypoxia and bed rest on markers of cardiometabolic risk</text></passage><passage><infon key="fpage">1344</infon><infon key="lpage">1352</infon><infon key="name_0">surname:Bloedon;given-names:LT</infon><infon key="name_1">surname:Dunbar;given-names:RL</infon><infon key="name_2">surname:Duffy;given-names:D</infon><infon key="name_3">surname:Pinell-Salles;given-names:P</infon><infon key="name_4">surname:Norris;given-names:R</infon><infon key="name_5">surname:DeGroot;given-names:BJ</infon><infon key="name_6">surname:Movva;given-names:R</infon><infon key="name_7">surname:Navab;given-names:M</infon><infon key="name_8">surname:Fogelman;given-names:AM</infon><infon key="name_9">surname:Rader;given-names:DJ</infon><infon key="pub-id_doi">10.1194/jlr.P800003-JLR200</infon><infon key="pub-id_pmid">18323573</infon><infon key="section_type">REF</infon><infon key="source">J Lipid Res</infon><infon key="type">ref</infon><infon key="volume">49</infon><infon key="year">2008</infon><offset>21242</offset><text>Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients</text></passage><passage><infon key="fpage">10316</infon><infon key="lpage">10320</infon><infon key="name_0">surname:Bowry;given-names:VW</infon><infon key="name_1">surname:Stanley;given-names:KK</infon><infon key="name_2">surname:Stocker;given-names:R</infon><infon key="pub-id_doi">10.1073/pnas.89.21.10316</infon><infon key="pub-id_pmid">1332045</infon><infon key="section_type">REF</infon><infon key="source">Proc Natl Acad Sci USA</infon><infon key="type">ref</infon><infon key="volume">89</infon><infon key="year">1992</infon><offset>21362</offset><text>High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors</text></passage><passage><infon key="name_0">surname:Cartolano;given-names:FD</infon><infon key="name_1">surname:Dias;given-names:GD</infon><infon key="name_2">surname:Miyamoto;given-names:S</infon><infon key="name_3">surname:Damasceno;given-names:NR</infon><infon key="pub-id_doi">10.3389/fnut.2021.767535</infon><infon key="pub-id_pmid">35281761</infon><infon key="section_type">REF</infon><infon key="source">Front Nutr</infon><infon key="type">ref</infon><infon key="year">2022</infon><offset>21474</offset><text>Omega-3 fatty acids improve functionality of high-density lipoprotein in individuals with high cardiovascular risk: a randomized, parallel, controlled and double-blind clinical trial</text></passage><passage><infon key="fpage">1429</infon><infon key="lpage">1433</infon><infon key="name_0">surname:Chatterjee;given-names:C</infon><infon key="name_1">surname:Sparks;given-names:DL</infon><infon key="pub-id_doi">10.1016/j.ajpath.2010.12.050</infon><infon key="pub-id_pmid">21406176</infon><infon key="section_type">REF</infon><infon key="source">Am J Pathol</infon><infon key="type">ref</infon><infon key="volume">178</infon><infon key="year">2011</infon><offset>21657</offset><text>Hepatic lipase, high density lipoproteins, and hypertriglyceridemia</text></passage><passage><infon key="fpage">99</infon><infon key="lpage">109</infon><infon key="name_0">surname:Chen;given-names:HC</infon><infon key="name_1">surname:Chou;given-names:CK</infon><infon key="name_2">surname:Lee;given-names:SD</infon><infon key="name_3">surname:Wang;given-names:JC</infon><infon key="name_4">surname:Yeh;given-names:SF</infon><infon key="pub-id_doi">10.1016/0166-3542(94)00083-K</infon><infon key="section_type">REF</infon><infon key="source">Antivir Res</infon><infon key="type">ref</infon><infon key="volume">1–2</infon><infon key="year">1995</infon><offset>21725</offset><text>Active compounds from Saussurea lappa Clarke that suppress hepatitis B virus surface antigen gene expression in human hepatoma cells</text></passage><passage><infon key="fpage">1657</infon><infon key="lpage">1664</infon><infon key="name_0">surname:Corsetti;given-names:JP</infon><infon key="name_1">surname:Ryan;given-names:D</infon><infon key="name_2">surname:Rainwater;given-names:DL</infon><infon key="name_3">surname:Moss;given-names:AJ</infon><infon key="name_4">surname:Zareba;given-names:W</infon><infon key="name_5">surname:Sparks;given-names:CE</infon><infon key="pub-id_doi">10.1161/ATVBAHA.110.207977</infon><infon key="pub-id_pmid">20489166</infon><infon key="section_type">REF</infon><infon key="source">Arterioscler Thromb Vasc Biol</infon><infon key="type">ref</infon><infon key="volume">30</infon><infon key="year">2010</infon><offset>21858</offset><text>Cholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels</text></passage><passage><infon key="fpage">2695</infon><infon key="lpage">2705</infon><infon key="name_0">surname:Dai;given-names:L</infon><infon key="name_1">surname:Datta;given-names:G</infon><infon key="name_2">surname:Zhang;given-names:Z</infon><infon key="name_3">surname:Gupta;given-names:H</infon><infon key="pub-id_doi">10.1194/jlr.M008086</infon><infon key="pub-id_pmid">20495214</infon><infon key="section_type">REF</infon><infon key="source">J Lipid Res</infon><infon key="type">ref</infon><infon key="volume">51</infon><infon key="year">2010</infon><offset>22039</offset><text>The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats</text></passage><passage><infon key="fpage">282</infon><infon key="issue">3</infon><infon key="lpage">286</infon><infon key="name_0">surname:Das;given-names:UN</infon><infon key="pub-id_doi">10.1016/j.arcmed.2020.03.004</infon><infon key="pub-id_pmid">32229155</infon><infon key="section_type">REF</infon><infon key="source">Arch Med Res</infon><infon key="type">ref</infon><infon key="volume">51</infon><infon key="year">2020</infon><offset>22139</offset><text>Can bioactive lipids inactivate coronavirus (COVID-19)?</text></passage><passage><infon key="fpage">768</infon><infon key="issue">6108</infon><infon key="lpage">772</infon><infon key="name_0">surname:Drakesmith;given-names:H</infon><infon key="name_1">surname:Prentice;given-names:AM</infon><infon key="pub-id_doi">10.1126/science.1224577</infon><infon key="pub-id_pmid">23139325</infon><infon key="section_type">REF</infon><infon key="source">Science</infon><infon key="type">ref</infon><infon key="volume">338</infon><infon key="year">2012</infon><offset>22195</offset><text>Hepcidin and the iron-infection axis</text></passage><passage><infon key="fpage">14983</infon><infon key="issue">37</infon><infon key="lpage">14988</infon><infon key="name_0">surname:El Kebir;given-names:D</infon><infon key="name_1">surname:Gjorstrup;given-names:P</infon><infon key="name_2">surname:Filep;given-names:JG</infon><infon key="pub-id_doi">10.1073/pnas.1206641109</infon><infon key="pub-id_pmid">22927428</infon><infon key="section_type">REF</infon><infon key="source">Proc Natl Acad Sci U S A</infon><infon key="type">ref</infon><infon key="volume">109</infon><infon key="year">2012</infon><offset>22232</offset><text>Resovin E1 promotes phagocytosis-induced neutrophil apoptosis and accelerates resolution of pulmonary inflammation</text></passage><passage><infon key="fpage">575e88</infon><infon key="name_0">surname:Filippas-Ntekouan;given-names:S</infon><infon key="name_1">surname:Liberopoulos;given-names:E</infon><infon key="name_2">surname:Elisaf;given-names:M</infon><infon key="pub-id_doi">10.1007/s15010-017-1022-3</infon><infon key="pub-id_pmid">28484991</infon><infon key="section_type">REF</infon><infon key="source">Infection</infon><infon key="type">ref</infon><infon key="volume">45</infon><infon key="year">2017</infon><offset>22347</offset><text>Lipid testing in infectious diseases: possible role in diagnosis and prognosis</text></passage><passage><infon key="fpage">ra79</infon><infon key="issue">389</infon><infon key="name_0">surname:Galvani;given-names:S</infon><infon key="name_1">surname:Sanson;given-names:M</infon><infon key="name_2">surname:Blaho;given-names:VA</infon><infon key="pub-id_doi">10.1126/scisignal.aaa2581</infon><infon key="pub-id_pmid">26268607</infon><infon key="section_type">REF</infon><infon key="source">Sci Signal</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">2015</infon><offset>22426</offset><text>HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation</text></passage><passage><infon key="fpage">538</infon><infon key="lpage">542</infon><infon key="name_0">surname:Ganz;given-names:T</infon><infon key="name_1">surname:Nemeth;given-names:E</infon><infon key="pub-id_doi">10.1182/asheducation-2011.1.538</infon><infon key="section_type">REF</infon><infon key="source">Hematol Am Soc Hematol Educ Program</infon><infon key="type">ref</infon><infon key="volume">2011</infon><infon key="year">2011</infon><offset>22555</offset><text>The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders</text></passage><passage><infon key="fpage">182</infon><infon key="issue">3</infon><infon key="lpage">187</infon><infon key="name_0">surname:Girelli;given-names:D</infon><infon key="name_1">surname:Marchi;given-names:G</infon><infon key="name_2">surname:Busti;given-names:F</infon><infon key="name_3">surname:Vianello;given-names:A</infon><infon key="pub-id_doi">10.1053/j.seminhematol.2021.07.001</infon><infon key="pub-id_pmid">34389110</infon><infon key="section_type">REF</infon><infon key="source">Semin Hematol</infon><infon key="type">ref</infon><infon key="volume">58</infon><infon key="year">2021</infon><offset>22650</offset><text>Iron metabolism in infections: focus on COVID-19</text></passage><passage><infon key="name_0">surname:Gomaa;given-names:HF</infon><infon key="name_1">surname:Abdelmalek;given-names:IB</infon><infon key="name_2">surname:Abdel-Wahhab;given-names:KG</infon><infon key="pub-id_doi">10.2174/1871530320666201016145502</infon><infon key="section_type">REF</infon><infon key="source">Endocr Metab Immune Disord Drug Targets</infon><infon key="type">ref</infon><infon key="year">2020</infon><offset>22699</offset><text>The anti-diabetic effect of some plant extracts against Streptozotocin-induced diabetes type 2 in male albino rats</text></passage><passage><infon key="fpage">1202</infon><infon key="lpage">1209</infon><infon key="name_0">surname:Hänel;given-names:P</infon><infon key="name_1">surname:Andréani;given-names:P</infon><infon key="name_2">surname:Gräler;given-names:MH</infon><infon key="pub-id_doi">10.1096/fj.06-7433com</infon><infon key="pub-id_pmid">17215483</infon><infon key="section_type">REF</infon><infon key="source">FASEB J</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="year">2007</infon><offset>22814</offset><text>Erythrocytes store and release sphingosine 1-phosphate in blood</text></passage><passage><infon key="fpage">2121</infon><infon key="lpage">2127</infon><infon key="name_0">surname:James;given-names:RW</infon><infon key="name_1">surname:Brulhart-Meynet;given-names:M-C</infon><infon key="name_2">surname:Singh;given-names:AK</infon><infon key="name_3">surname:Riederer;given-names:B</infon><infon key="name_4">surname:Seidler;given-names:U</infon><infon key="name_5">surname:Out;given-names:R</infon><infon key="name_6">surname:Van Berkel;given-names:T</infon><infon key="name_7">surname:Deakin;given-names:S</infon><infon key="pub-id_doi">10.1161/ATVBAHA.110.209122</infon><infon key="pub-id_pmid">20724701</infon><infon key="section_type">REF</infon><infon key="source">Arterioscler Thromb Vasc Biol</infon><infon key="type">ref</infon><infon key="volume">30</infon><infon key="year">2010</infon><offset>22878</offset><text>The scavenger receptor class B, type I is a primary determinant of paraoxonase-1 association with high-density lipoproteins</text></passage><passage><infon key="fpage">101721</infon><infon key="name_0">surname:Kalyanaraman;given-names:B</infon><infon key="pub-id_doi">10.1016/j.redox.2020.101721</infon><infon key="section_type">REF</infon><infon key="source">Redox Biol</infon><infon key="type">ref</infon><infon key="volume">2020</infon><infon key="year">2020</infon><offset>23002</offset><text>Do free radical network and oxidative stress disparities in African Americans enhance their vulnerability to SARS-CoV-2 infection and COVID-19 severity?</text></passage><passage><infon key="fpage">171</infon><infon key="lpage">177</infon><infon key="name_0">surname:Kang;given-names:JS</infon><infon key="name_1">surname:Yoon;given-names:YD</infon><infon key="name_2">surname:Lee;given-names:KH</infon><infon key="name_3">surname:Park;given-names:SK</infon><infon key="name_4">surname:Kim;given-names:HM</infon><infon key="pub-id_doi">10.1016/j.bbrc.2003.11.109</infon><infon key="pub-id_pmid">14672714</infon><infon key="section_type">REF</infon><infon key="source">Biochem Biophys Res Comm</infon><infon key="type">ref</infon><infon key="volume">313</infon><infon key="year">2004</infon><offset>23155</offset><text>Costunolide inhibits interleukin-1b expression by down-regulation of AP-1 and MAPK activity in LPS-stimulated RAW 264.7 cells</text></passage><passage><infon key="fpage">312</infon><infon key="lpage">318</infon><infon key="name_0">surname:Kontush;given-names:A</infon><infon key="name_1">surname:Chapman;given-names:MJ</infon><infon key="pub-id_doi">10.1097/MOL.0b013e32833bcdc1</infon><infon key="pub-id_pmid">20581677</infon><infon key="section_type">REF</infon><infon key="source">Curr Opin Lipidol</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="year">2010</infon><offset>23281</offset><text>Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities</text></passage><passage><infon key="fpage">16</infon><infon key="lpage">26</infon><infon key="name_0">surname:Kurano;given-names:M</infon><infon key="name_1">surname:Yatomi;given-names:Y</infon><infon key="pub-id_doi">10.5551/jat.RV17010</infon><infon key="pub-id_pmid">28724841</infon><infon key="section_type">REF</infon><infon key="source">J Atheroscler Thromb</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">2018</infon><offset>23372</offset><text>Sphingosine 1-phosphate and atherosclerosis</text></passage><passage><infon key="fpage">867</infon><infon key="lpage">881</infon><infon key="name_0">surname:Kurano;given-names:M</infon><infon key="name_1">surname:Tsukamot;given-names:K</infon><infon key="name_2">surname:Shimizu;given-names:T</infon><infon key="pub-id_doi">10.2337/db19-0811</infon><infon key="pub-id_pmid">31915150</infon><infon key="section_type">REF</infon><infon key="source">Diabetes</infon><infon key="type">ref</infon><infon key="volume">69</infon><infon key="year">2020</infon><offset>23416</offset><text>Protection against insulin resistance by apolipoprotein M/sphingosine-1-phosphate</text></passage><passage><infon key="fpage">120138</infon><infon key="name_0">surname:Lammari;given-names:N</infon><infon key="name_1">surname:Demautis;given-names:T</infon><infon key="name_2">surname:Louaer;given-names:O</infon><infon key="name_3">surname:Meniai;given-names:AH</infon><infon key="pub-id_doi">10.1016/j.ijpharm.2020.120138</infon><infon key="pub-id_pmid">33278497</infon><infon key="section_type">REF</infon><infon key="source">Int J Pharm</infon><infon key="type">ref</infon><infon key="volume">593</infon><infon key="year">2021</infon><offset>23498</offset><text>Nanocapsules containing Saussurea lappa essential oil: formulation, characterization, antidiabetic, anti-cholinesterase and anti-inflammatory potentials</text></passage><passage><infon key="name_0">surname:Lassale;given-names:C</infon><infon key="name_1">surname:Hamer;given-names:M</infon><infon key="name_2">surname:Hernaez;given-names:A</infon><infon key="name_3">surname:Gale;given-names:CR</infon><infon key="pub-id_doi">10.1101/2021.01.20.21250152</infon><infon key="pub-id_pmid">33564795</infon><infon key="section_type">REF</infon><infon key="source">medRxiv</infon><infon key="type">ref</infon><infon key="year">2021</infon><offset>23651</offset><text>Batty GD (2021) High density lipoprotein cholesterol and risk of subsequent COVID-19 hospitalisation: the UK Biobank study</text></passage><passage><infon key="fpage">646</infon><infon key="issue">6</infon><infon key="lpage">655</infon><infon key="name_0">surname:Li;given-names:H</infon><infon key="name_1">surname:Xiang;given-names:X</infon><infon key="pub-id_doi">10.1016/j.jinf.2020.03.035</infon><infon key="pub-id_pmid">32277967</infon><infon key="section_type">REF</infon><infon key="source">J Infect</infon><infon key="type">ref</infon><infon key="volume">80</infon><infon key="year">2020</infon><offset>23774</offset><text>Serum amyloid A, a biomarker of severe coronavirus disease and poor prognosis</text></passage><passage><infon key="fpage">81</infon><infon key="lpage">86</infon><infon key="name_0">surname:Lingappan;given-names:K</infon><infon key="pub-id_doi">10.1016/j.cotox.2017.11.002</infon><infon key="section_type">REF</infon><infon key="source">Curr Opin Toxico</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2018</infon><offset>23852</offset><text>NF-κB in oxidative stress</text></passage><passage><infon key="fpage">951</infon><infon key="lpage">961</infon><infon key="name_0">surname:Liu;given-names:Y</infon><infon key="name_1">surname:Wada;given-names:R</infon><infon key="name_10">surname:Liu;given-names:CH</infon><infon key="name_11">surname:Hla;given-names:T</infon><infon key="name_12">surname:Spiegel;given-names:S</infon><infon key="name_13">surname:Proia;given-names:RL</infon><infon key="name_2">surname:Yamashita;given-names:T</infon><infon key="name_3">surname:Mi;given-names:Y</infon><infon key="name_4">surname:Deng;given-names:CX</infon><infon key="name_5">surname:Hobson;given-names:JP</infon><infon key="name_6">surname:Rosenfeldt;given-names:HM</infon><infon key="name_7">surname:Nava;given-names:VE</infon><infon key="name_8">surname:Chae;given-names:SS</infon><infon key="name_9">surname:Lee;given-names:MJ</infon><infon key="pub-id_doi">10.1172/JCI10905</infon><infon key="pub-id_pmid">11032855</infon><infon key="section_type">REF</infon><infon key="source">J Clin Invest</infon><infon key="type">ref</infon><infon key="volume">106</infon><infon key="year">2000</infon><offset>23882</offset><text>Edg-1, the G protein–coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation</text></passage><passage><infon key="fpage">e13424</infon><infon key="issue">1</infon><infon key="name_0">surname:Marfia;given-names:G</infon><infon key="name_1">surname:Navone;given-names:S</infon><infon key="name_2">surname:Guarnaccia;given-names:L</infon><infon key="pub-id_doi">10.15252/emmm.202013424</infon><infon key="pub-id_pmid">33190411</infon><infon key="section_type">REF</infon><infon key="source">EMBO Mol Med</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2021</infon><offset>23988</offset><text>Decreased serum level of sphingosine-1-phosphate: a novel predictor of clinical severity in COVID-19</text></passage><passage><infon key="fpage">172</infon><infon key="lpage">178</infon><infon key="name_0">surname:McEneny;given-names:J</infon><infon key="name_1">surname:McKavanagh;given-names:P</infon><infon key="name_2">surname:York;given-names:E</infon><infon key="name_3">surname:Nadeem;given-names:N</infon><infon key="name_4">surname:Harbinson;given-names:M</infon><infon key="name_5">surname:Stevenson;given-names:M</infon><infon key="pub-id_doi">10.1016/j.atherosclerosis.2015.11.018</infon><infon key="pub-id_pmid">26647373</infon><infon key="section_type">REF</infon><infon key="source">Atherosclerosis</infon><infon key="type">ref</infon><infon key="volume">244</infon><infon key="year">2016</infon><offset>24089</offset><text>Serum- and HDL3-serum amyloid A and HDL3-LCAT activity are influenced by increased CVD-burden</text></passage><passage><infon key="fpage">861</infon><infon key="issue">4</infon><infon key="lpage">862</infon><infon key="name_0">surname:Means;given-names:RT;suffix:Jr</infon><infon key="pub-id_doi">10.1136/jim-2022-002362</infon><infon key="pub-id_pmid">35410915</infon><infon key="section_type">REF</infon><infon key="source">J Investig Med</infon><infon key="type">ref</infon><infon key="volume">70</infon><infon key="year">2022</infon><offset>24183</offset><text>Hepcidin, iron, and COVID-19: is there an erythroid connection?</text></passage><passage><infon key="fpage">112</infon><infon key="issue">1</infon><infon key="lpage">125</infon><infon key="name_0">surname:Morita;given-names:M</infon><infon key="name_1">surname:Kuba;given-names:K</infon><infon key="name_2">surname:Ichikawa;given-names:A</infon><infon key="pub-id_doi">10.1016/j.cell.2013.02.027</infon><infon key="pub-id_pmid">23477864</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">153</infon><infon key="year">2013</infon><offset>24247</offset><text>The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza</text></passage><passage><infon key="fpage">704</infon><infon key="issue">6</infon><infon key="lpage">712</infon><infon key="name_0">surname:Moriyama;given-names:K</infon><infon key="name_1">surname:Takahashi;given-names:E</infon><infon key="pub-id_doi">10.5551/jat.32896</infon><infon key="pub-id_pmid">26686740</infon><infon key="section_type">REF</infon><infon key="source">J Atheroscler Thromb</infon><infon key="type">ref</infon><infon key="volume">23</infon><infon key="year">2016</infon><offset>24346</offset><text>HDL2/HDL3 ratio changes, metabolic syndrome markers, and other factors in a Japanese population</text></passage><passage><infon key="fpage">1495</infon><infon key="lpage">1508</infon><infon key="name_0">surname:Navab;given-names:M</infon><infon key="name_1">surname:Hama;given-names:SY</infon><infon key="name_2">surname:Anantharamaiah;given-names:GM</infon><infon key="name_3">surname:Hassan;given-names:K</infon><infon key="pub-id_doi">10.1016/S0022-2275(20)33462-3</infon><infon key="pub-id_pmid">10974057</infon><infon key="section_type">REF</infon><infon key="source">J Lipid Res</infon><infon key="type">ref</infon><infon key="volume">41</infon><infon key="year">2000</infon><offset>24442</offset><text>Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3</text></passage><passage><infon key="fpage">3215</infon><infon key="lpage">3220</infon><infon key="name_0">surname:Navab;given-names:M</infon><infon key="name_1">surname:Anantharamaiah;given-names:GM</infon><infon key="name_2">surname:Reddy;given-names:ST</infon><infon key="name_3">surname:Hama;given-names:S</infon><infon key="pub-id_doi">10.1161/01.CIR.0000134275.90823.87</infon><infon key="pub-id_pmid">15197147</infon><infon key="section_type">REF</infon><infon key="source">Circulation</infon><infon key="type">ref</infon><infon key="volume">109</infon><infon key="year">2004</infon><offset>24570</offset><text>Oral D-4F causes formation of pre-β high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice</text></passage><passage><infon key="fpage">1325</infon><infon key="lpage">1331</infon><infon key="name_0">surname:Navab;given-names:M</infon><infon key="name_1">surname:Anantharamaiah;given-names:GM</infon><infon key="name_10">surname:Fogelman;given-names:AM</infon><infon key="name_2">surname:Reddy;given-names:ST</infon><infon key="name_3">surname:Hama;given-names:S</infon><infon key="name_4">surname:Hough;given-names:G</infon><infon key="name_5">surname:Grijalva;given-names:VR</infon><infon key="name_6">surname:Yu;given-names:N</infon><infon key="name_7">surname:Ansell;given-names:BJ</infon><infon key="name_8">surname:Datta;given-names:G</infon><infon key="name_9">surname:Garber;given-names:DW</infon><infon key="pub-id_doi">10.1371/journal.pone.0226931</infon><infon key="pub-id_pmid">15831812</infon><infon key="section_type">REF</infon><infon key="source">Arterioscler Thromb Vasc Biol</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">2005</infon><offset>24781</offset><text>Apolipoprotein A-I mimetic peptides</text></passage><passage><infon key="fpage">2090</infon><infon key="issue">5704</infon><infon key="lpage">2093</infon><infon key="name_0">surname:Nemeth;given-names:E</infon><infon key="name_1">surname:Tuttle;given-names:MS</infon><infon key="name_2">surname:Powelson;given-names:J</infon><infon key="name_3">surname:Vaughn;given-names:MB</infon><infon key="name_4">surname:Donovan;given-names:A</infon><infon key="name_5">surname:Ward;given-names:DM</infon><infon key="name_6">surname:Ganz;given-names:T</infon><infon key="name_7">surname:Kaplan;given-names:J</infon><infon key="pub-id_doi">10.1126/science.1104742</infon><infon key="pub-id_pmid">15514116</infon><infon key="section_type">REF</infon><infon key="source">Science</infon><infon key="type">ref</infon><infon key="volume">306</infon><infon key="year">2004</infon><offset>24817</offset><text>Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization</text></passage><passage><infon key="fpage">138859</infon><infon key="name_0">surname:Nikhat;given-names:S</infon><infon key="name_1">surname:Fazil;given-names:M</infon><infon key="pub-id_doi">10.1016/j.scitotenv.2020.138859</infon><infon key="pub-id_pmid">32334163</infon><infon key="section_type">REF</infon><infon key="source">Sci Total Environ</infon><infon key="type">ref</infon><infon key="volume">728</infon><infon key="year">2020</infon><offset>24916</offset><text>Overview of Covid-19; its prevention and management in the light of Unani medicine</text></passage><passage><infon key="fpage">569</infon><infon key="lpage">581</infon><infon key="name_0">surname:Nofer;given-names:JR</infon><infon key="name_1">surname:van der Giet;given-names:M</infon><infon key="name_10">surname:Schäfers;given-names:M</infon><infon key="name_11">surname:Fobker;given-names:M</infon><infon key="name_12">surname:Zidek;given-names:W</infon><infon key="name_13">surname:Assmann;given-names:G</infon><infon key="name_14">surname:Chun;given-names:J</infon><infon key="name_15">surname:Levkau;given-names:B</infon><infon key="name_2">surname:Tölle;given-names:M</infon><infon key="name_3">surname:Wolinska;given-names:I</infon><infon key="name_4">surname:von Wnuck;given-names:LK</infon><infon key="name_5">surname:Baba;given-names:HA</infon><infon key="name_6">surname:Tietge;given-names:UJ</infon><infon key="name_7">surname:Gödecke;given-names:A</infon><infon key="name_8">surname:Ishii;given-names:I</infon><infon key="name_9">surname:Kleuser;given-names:B</infon><infon key="pub-id_doi">10.1172/JCI200418004</infon><infon key="pub-id_pmid">14966566</infon><infon key="section_type">REF</infon><infon key="source">J Clin Invest</infon><infon key="type">ref</infon><infon key="volume">113</infon><infon key="year">2004</infon><offset>24999</offset><text>HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3</text></passage><passage><infon key="fpage">1997</infon><infon key="name_0">surname:Pal;given-names:A</infon><infon key="name_1">surname:Gowdy;given-names:KM</infon><infon key="name_2">surname:Oestreich;given-names:KJ</infon><infon key="name_3">surname:Beck;given-names:M</infon><infon key="name_4">surname:Shaikh;given-names:SR</infon><infon key="pub-id_doi">10.3389/fimmu.2020.01997</infon><infon key="pub-id_pmid">32983141</infon><infon key="section_type">REF</infon><infon key="source">Front Immunol</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">2020</infon><offset>25078</offset><text>Obesity driven deficiencies of specialized pro-resolving mediators may drive adverse outcomes during SARS-CoV-2infection</text></passage><passage><infon key="fpage">120</infon><infon key="issue">Suppl 2</infon><infon key="lpage">125</infon><infon key="name_0">surname:Popko;given-names:K</infon><infon key="name_1">surname:Gorska;given-names:EA</infon><infon key="name_2">surname:Plywaczewski;given-names:A</infon><infon key="name_3">surname:Stoklosa;given-names:A</infon><infon key="name_4">surname:Gorecka;given-names:D</infon><infon key="name_5">surname:Pyrzak;given-names:B</infon><infon key="name_6">surname:Demkow;given-names:U</infon><infon key="pub-id_doi">10.1186/2047-783X-15-S2-120</infon><infon key="pub-id_pmid">21147638</infon><infon key="section_type">REF</infon><infon key="source">Eur J Med Res</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">2010</infon><offset>25199</offset><text>Proinflammatory cytokines IL-6 and TNF-α and the development of inflammation in obese subjects</text></passage><passage><infon key="fpage">2829</infon><infon key="issue">11</infon><infon key="lpage">2845</infon><infon key="name_0">surname:Radzikowska;given-names:U</infon><infon key="name_1">surname:Ding;given-names:M</infon><infon key="name_2">surname:Tan;given-names:G</infon><infon key="pub-id_doi">10.1111/all.14429</infon><infon key="pub-id_pmid">32496587</infon><infon key="section_type">REF</infon><infon key="source">Allergy</infon><infon key="type">ref</infon><infon key="volume">75</infon><infon key="year">2020</infon><offset>25298</offset><text>Distribution of ACE2, CD147, cyclophilins, CD26 and other SARSCoV-2 associated molecules in human tissues and immune cells in health and disease</text></passage><passage><infon key="fpage">402</infon><infon key="name_0">surname:Rajasundaram;given-names:S</infon><infon key="pub-id_doi">10.3389/fimmu.2018.00402</infon><infon key="pub-id_pmid">29559972</infon><infon key="section_type">REF</infon><infon key="source">Front Immunol</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2018</infon><offset>25443</offset><text>Adenosine-A2A receptor signaling in the immunopathogenesis of experimental autoimmune encephalomyelitis</text></passage><passage><infon key="fpage">H1059</infon><infon key="issue">5</infon><infon key="lpage">H1068</infon><infon key="name_0">surname:Robinson;given-names:FA</infon><infon key="name_1">surname:Mihealsick;given-names:RP</infon><infon key="name_2">surname:Wagener;given-names:BM</infon><infon key="pub-id_doi">10.1152/ajpheart.00681.2020</infon><infon key="pub-id_pmid">33036546</infon><infon key="section_type">REF</infon><infon key="source">Am J Physiol Heart Circ Physiol</infon><infon key="type">ref</infon><infon key="volume">319</infon><infon key="year">2020</infon><offset>25547</offset><text>Role of angiotensin-converting enzyme 2 and pericytes in cardiac complications of COVID-19 infection</text></passage><passage><infon key="fpage">349</infon><infon key="issue">5</infon><infon key="lpage">361</infon><infon key="name_0">surname:Serhan;given-names:CN</infon><infon key="name_1">surname:Chiang;given-names:N</infon><infon key="name_2">surname:Van Dyke;given-names:TE</infon><infon key="pub-id_doi">10.1038/nri2294</infon><infon key="pub-id_pmid">18437155</infon><infon key="section_type">REF</infon><infon key="source">Nat Rev Immunol</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">2008</infon><offset>25648</offset><text>Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators</text></passage><passage><infon key="fpage">12224</infon><infon key="lpage">12229</infon><infon key="name_0">surname:Shao;given-names:B</infon><infon key="name_1">surname:Cavigioli;given-names:G</infon><infon key="name_2">surname:Brot;given-names:N</infon><infon key="name_3">surname:Oda;given-names:MN</infon><infon key="name_4">surname:Heinecke;given-names:JW</infon><infon key="pub-id_doi">10.1073/pnas.0802025105</infon><infon key="pub-id_pmid">18719109</infon><infon key="section_type">REF</infon><infon key="source">Proc Natl Acad Sci USA</infon><infon key="type">ref</infon><infon key="volume">105</infon><infon key="year">2008</infon><offset>25730</offset><text>Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I</text></passage><passage><infon key="fpage">1097</infon><infon key="lpage">1105</infon><infon key="name_0">surname:Shibuya;given-names:M</infon><infon key="pub-id_doi">10.1177/1947601911423031</infon><infon key="pub-id_pmid">22866201</infon><infon key="section_type">REF</infon><infon key="source">Genes Cancer</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="year">2011</infon><offset>25811</offset><text>Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies</text></passage><passage><infon key="fpage">598</infon><infon key="lpage">605</infon><infon key="name_0">surname:Sitkovsky;given-names:MV</infon><infon key="name_1">surname:Hatfield;given-names:S</infon><infon key="name_2">surname:Abbott;given-names:R</infon><infon key="name_3">surname:Belikoff;given-names:B</infon><infon key="name_4">surname:Lukashev;given-names:D</infon><infon key="name_5">surname:Ohta;given-names:A</infon><infon key="pub-id_doi">10.1158/2326-6066.CIR-14-0075</infon><infon key="pub-id_pmid">24990240</infon><infon key="section_type">REF</infon><infon key="source">Cancer Immunol Res</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="year">2014</infon><offset>25961</offset><text>Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists</text></passage><passage><infon key="fpage">C1538</infon><infon key="lpage">C1548</infon><infon key="name_0">surname:Smythies;given-names:LE</infon><infon key="name_1">surname:White;given-names:CR</infon><infon key="name_2">surname:Maheshwari;given-names:A</infon><infon key="name_3">surname:Palgunachari</infon><infon key="pub-id_doi">10.1152/ajpcell.00467.2009</infon><infon key="pub-id_pmid">20219948</infon><infon key="section_type">REF</infon><infon key="source">Am J Physiol Cell Physiol</infon><infon key="type">ref</infon><infon key="volume">298</infon><infon key="year">2010</infon><offset>26065</offset><text>Apolipoprotein A-I mimetic 4F alters the function of human monocyte-derived macrophages</text></passage><passage><infon key="fpage">265</infon><infon key="issue">4</infon><infon key="lpage">274</infon><infon key="name_0">surname:Soran;given-names:H</infon><infon key="name_1">surname:Younis;given-names:NN</infon><infon key="name_2">surname:Charlton-Menys;given-names:V</infon><infon key="name_3">surname:Durrington;given-names:P</infon><infon key="pub-id_doi">10.1097/MOL.0b013e32832ec141</infon><infon key="pub-id_pmid">19550323</infon><infon key="section_type">REF</infon><infon key="source">Curr Opin Lipidol</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">2009</infon><offset>26153</offset><text>Variation in paraoxonase-1 activity and atherosclerosis</text></passage><passage><infon key="fpage">9843</infon><infon key="issue">8</infon><infon key="lpage">9853</infon><infon key="name_0">surname:Sorokin;given-names:AV</infon><infon key="name_1">surname:Karathanasis;given-names:SK</infon><infon key="name_2">surname:Yang;given-names:Z</infon><infon key="name_3">surname:Freeman;given-names:L</infon><infon key="name_4">surname:Kotani;given-names:K</infon><infon key="pub-id_doi">10.1096/fj.202001451</infon><infon key="section_type">REF</infon><infon key="source">FASEB</infon><infon key="type">ref</infon><infon key="volume">34</infon><infon key="year">2020</infon><offset>26209</offset><text>COVID-19—Associated dyslipidemia: implications for mechanism of impaired resolution and novel therapeutic approaches</text></passage><passage><infon key="fpage">680</infon><infon key="lpage">687</infon><infon key="name_0">surname:Steck;given-names:TL</infon><infon key="name_1">surname:Lange;given-names:Y</infon><infon key="pub-id_doi">10.1016/j.tcb.2010.08.007</infon><infon key="pub-id_pmid">20843692</infon><infon key="section_type">REF</infon><infon key="source">Trends Cell Biol</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">2010</infon><offset>26328</offset><text>Cell cholesterol homeostasis: mediation by active cholesterol</text></passage><passage><infon key="fpage">389</infon><infon key="lpage">391</infon><infon key="name_0">surname:Teuwen;given-names:LA</infon><infon key="name_1">surname:Geldhof;given-names:V</infon><infon key="name_2">surname:Pasut;given-names:A</infon><infon key="name_3">surname:Carmeliet;given-names:P</infon><infon key="pub-id_doi">10.1038/s41577-020-0343-0</infon><infon key="pub-id_pmid">32439870</infon><infon key="section_type">REF</infon><infon key="source">Nat Rev Immunol</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">2020</infon><offset>26390</offset><text>COVID-19: the vasculature unleashed</text></passage><passage><infon key="fpage">434</infon><infon key="issue">3</infon><infon key="lpage">440</infon><infon key="name_0">surname:Ulrich;given-names:H</infon><infon key="name_1">surname:Pillat;given-names:M</infon><infon key="pub-id_doi">10.1007/s12015-020-09976-7</infon><infon key="pub-id_pmid">32307653</infon><infon key="section_type">REF</infon><infon key="source">Stem Cell Rev Rep</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2020</infon><offset>26426</offset><text>CD147 as a target for COVID-19 treatment: suggested effects of azithromycin and stem cell engagement</text></passage><passage><infon key="fpage">30825</infon><infon key="lpage">30835</infon><infon key="name_0">surname:Undurti;given-names:A</infon><infon key="name_1">surname:Huang;given-names:Y</infon><infon key="name_2">surname:Lupica;given-names:JA</infon><infon key="name_3">surname:Smith;given-names:JD</infon><infon key="pub-id_doi">10.1074/jbc.M109.047605</infon><infon key="pub-id_pmid">19726691</infon><infon key="section_type">REF</infon><infon key="source">J Biol Chem</infon><infon key="type">ref</infon><infon key="volume">284</infon><infon key="year">2009</infon><offset>26527</offset><text>Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle</text></passage><passage><infon key="fpage">2758</infon><infon key="lpage">2767</infon><infon key="name_0">surname:Van Lenten;given-names:BJ</infon><infon key="name_1">surname:Hama;given-names:SY</infon><infon key="name_2">surname:Beer;given-names:FC</infon><infon key="name_3">surname:Stafforini;given-names:DM</infon><infon key="name_4">surname:McIntyre;given-names:TM</infon><infon key="name_5">surname:Prescott;given-names:SM</infon><infon key="name_6">surname:La Du;given-names:BN</infon><infon key="name_7">surname:Fogelman;given-names:AM</infon><infon key="name_8">surname:Navab;given-names:M</infon><infon key="pub-id_doi">10.1172/JCI118345</infon><infon key="pub-id_pmid">8675645</infon><infon key="section_type">REF</infon><infon key="source">J Clin Invest</infon><infon key="type">ref</infon><infon key="volume">96</infon><infon key="year">1995</infon><offset>26625</offset><text>Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures</text></passage><passage><infon key="fpage">283</infon><infon key="issue">1</infon><infon key="name_0">surname:Wang;given-names:K</infon><infon key="name_1">surname:Chen;given-names:W</infon><infon key="name_2">surname:Zhou;given-names:Y</infon><infon key="pub-id_doi">10.1038/s41392-020-00426-x</infon><infon key="pub-id_pmid">33277466</infon><infon key="section_type">REF</infon><infon key="source">Signal Transduct Target Ther</infon><infon key="type">ref</infon><infon key="volume">5</infon><infon key="year">2020</infon><offset>26791</offset><text>SARSCoV-2 invades host cells via a novel route: CD147-spike protein</text></passage><passage><infon key="fpage">23698</infon><infon key="lpage">23707</infon><infon key="name_0">surname:Watanabe;given-names:J</infon><infon key="name_1">surname:Chou;given-names:KJ</infon><infon key="name_2">surname:Liao;given-names:JC</infon><infon key="name_3">surname:Miao;given-names:Y</infon><infon key="pub-id_doi">10.1074/jbc.M702163200</infon><infon key="pub-id_pmid">17556366</infon><infon key="section_type">REF</infon><infon key="source">J Biol Chem</infon><infon key="type">ref</infon><infon key="volume">282</infon><infon key="year">2007</infon><offset>26859</offset><text>Differential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice. A novel biomarker of atherosclerosis</text></passage><passage><infon key="fpage">18292</infon><infon key="lpage">18301</infon><infon key="name_0">surname:Watanabe;given-names:J</infon><infon key="name_1">surname:Grijalva;given-names:V</infon><infon key="name_2">surname:Hama;given-names:S</infon><infon key="name_3">surname:Barbour;given-names:K</infon><infon key="name_4">surname:Berger;given-names:FG</infon><infon key="name_5">surname:Navab;given-names:M</infon><infon key="pub-id_doi">10.1074/jbc.M109.017202</infon><infon key="pub-id_pmid">19433579</infon><infon key="section_type">REF</infon><infon key="source">J Biol Chem</infon><infon key="type">ref</infon><infon key="volume">284</infon><infon key="year">2009</infon><offset>27018</offset><text>Hemoglobin and its scavenger protein haptoglobin associate with apoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>27193</offset><text>Wenzhong L, Hualan L (2020a) COVID-19 Disease: ORF8 and surface glycoprotein inhibit heme metabolism by binding to porphyrin. ChemRxiv; Preprint. 10.26434/chemrxiv.11938173.v3</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>27369</offset><text>Wenzhong L, Hualan L (2020b) COVID-19: Attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. ChemRxiv. Preprint. 10.26434/chemrxiv.11938173.v8</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>27558</offset><text>Yang Y, Zhu Z, Fan L, Ye S, Lou K, Hua X (2020) Low serum level of apolipoprotein A1 is an indicator of severity in patients with coronavirus disease 2019. Res Sq preprint, version 1, posted 2020 May 29. 10.21203/rs.3.rs-31251/v1</text></passage><passage><infon key="fpage">3007</infon><infon key="issue">4</infon><infon key="lpage">3016</infon><infon key="name_0">surname:Zewinger;given-names:S</infon><infon key="name_1">surname:Drechsler;given-names:C</infon><infon key="name_2">surname:Kleber;given-names:ME</infon><infon key="pub-id_doi">10.1093/eurheartj/ehv352</infon><infon key="pub-id_pmid">26248570</infon><infon key="section_type">REF</infon><infon key="source">Eur Heart J</infon><infon key="type">ref</infon><infon key="volume">36</infon><infon key="year">2015</infon><offset>27788</offset><text>Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk</text></passage><passage><infon key="fpage">529</infon><infon key="lpage">541</infon><infon key="name_0">surname:Zheng;given-names:L</infon><infon key="name_1">surname:Nukuna;given-names:B</infon><infon key="name_2">surname:Brennan;given-names:M-L</infon><infon key="pub-id_doi">10.1172/JCI200421109</infon><infon key="pub-id_pmid">15314690</infon><infon key="section_type">REF</infon><infon key="source">J Clin Invest</infon><infon key="type">ref</infon><infon key="volume">114</infon><infon key="year">2004</infon><offset>27867</offset><text>Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease</text></passage><passage><infon key="fpage">1054</infon><infon key="lpage">1063</infon><infon key="name_0">surname:Zhou;given-names:F</infon><infon key="name_1">surname:Yu;given-names:T</infon><infon key="name_2">surname:Du;given-names:R</infon><infon key="pub-id_doi">10.1016/S0140-6736(20)30566-3</infon><infon key="pub-id_pmid">32171076</infon><infon key="section_type">REF</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="volume">395</infon><infon key="year">2020</infon><offset>28014</offset><text>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</text></passage></document></collection>
